IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques


  • 16/08/2016 - Press release

    Catalogue described of genetic mutations, their frequency and arrangement on the DNA

    An international project, The Exome Aggregation Consortium (ExAC), involving researchers from the IMIM (Hospital del Mar Medical Research Institute) as the only Spanish participant, has analysed the DNA that encodes proteins in 60,706 individuals from different ethnic groups and has presented the international scientific community with a catalogue that contains the mutations identified, their frequency and their arrangement on the DNA.The study has been published in the journal Nature and involved the analysis of ten times more individuals than in any previous study. DNA is the molecule within our cells that contains the information for making proteins, in the form of a sequence of four letters or bases [adenine (A), guanine (G ), thymine (T) and cytosine (C)]. In recent years we have developed technologies to sequence, i.e., read the order of these bases in a person's DNA. Changing one of these bases can sometimes alter the protein that the cell makes and lead to illness. For this reason, it is important to know what the normal sequence of bases in DNA is, the frequency of mutations (changes in the sequence of these bases), and where these changes take place, by making a catalogue and map of DNA mutations in humans.

    Més informació "Catalogue described of genetic mutations, their frequency and arrangement on the DNA"

  • 02/08/2016 - Press release

    Gene regulation in a hibernating primate studied for the first time

    A study including the IMIM (Hospital del Mar Medical Research Institute), the Duke Lemur Center, and Duke University has, for the first time, been looking at gene regulation in hibernating primates. They studied the fat-tailed dwarf lemur (Cheirogaleus medius). This is a very little-studied species and exceptional as it is the only primate capable of hibernating, subsisting on the lipids it has stored in its tail over the rest of the year. The project is also one of the few works on hibernation that uses a modern technique known as RNAseq which provides a global view of which genes are expressed and quantifies these. This is the first genomic data on this species.

    Més informació "Gene regulation in a hibernating primate studied for the first time"

  • 29/07/2016 - Press release

    The IMIM takes part in the first major open source drug discovery trial

    The prestigious journal PLoS Pathogens has just published an article on the results of the Malaria Box project, an initiative of the Medicines for Malaria Venture that has given free, open access to new families of antimalarial molecules to 200 laboratories from 30 countries. The purpose of the project is to encourage new pharmacological discoveries that make it possible to fight neglected diseases and other illnesses and, for the moment, it has already initiated more than a dozen projects aimed at developing new drugs for various diseases. The Systems Pharmacology research group at the IMIM was the only Catalan participant in this extensive study that also involved three other Spanish centres, in the Basque country (BIOBIDE), Galicia (University of Santiago de Compostela) and Madrid (GlaxoSmithKline R&D). 

    Més informació "The IMIM takes part in the first major open source drug discovery trial"

  • 28/07/2016 - Press release

    Hospital del Mar develops an innovative calculator to predict the risk of atrial fibrillation

    Cardiologists at the Hospital del Mar and researchers from the Hospital del Mar Medical Research Institute (IMIM) have developed a new tool that enables them to estimate atrial fibrillation risk using electrocardiogram indicators, basic clinical data, and parameters obtained through Holter monitors (small electronic devices that record and store a patient's electrocardiogram for 24 hours). The results of the project have just been published in the International Journal of Cardiology. Atrial fibrillation is a disease characterised by uncoordinated and disorganised atrial beats that produce a rapid and irregular heart rate. It is estimated that it affects between 1.5 and 2% of people in the developed world and the percentage increases with age.

    Més informació "Hospital del Mar develops an innovative calculator to predict the risk of atrial fibrillation"

  • 20/07/2016 - Press release

    A combination of therapies improves lung cancer treatment

    Lung cancer is the most deadly cancer in the world, causing more than one and a half million deaths a year. The most common subtype of lung cancer is adenocarcinoma. The presence of other underlying conditions, such as chronic obstructive pulmonary disease (COPD), which is also responsible for a high mortality rate in industrialised regions, increases the risk of developing it. Despite recent progress in therapeutic strategies for combatting this disease, the majority of patients who are diagnosed do not survive for more than five years. It is a cancer that can develop silently for many months and, in some cases, the symptoms can be confused with other diseases, such as the already-mentioned COPD. This is why it is usually diagnosed in very advanced stages. To all these impediments, it is necessary to add the difficulty of finding an appropriate treatment for each patient, since there is a high level of resistance to currently-used drugs. 

    Més informació "A combination of therapies improves lung cancer treatment"

  • 06/07/2016 - Press release

    System developed for self-management of cardiovascular risk

    ICS Girona primary healthcare is carrying out a cardiovascular risk self-screening study (ACRISC), in which a thousand people are participating, for the self-management of cardiovascular disease risk. Through software developed specifically for this project, the users take part in the collection and processing of their health data (e.g., blood pressure, lipid profile, weight, and eating habits) and the system, based on the principles of empowerment and interactivity, offers each person tailor-made recommendations, particularly with regard to their diet and physical activity. The study is a collaboration between the Mar Institute of Medical Research (IMIM), the Primary Healthcare Research Support Unit in Girona (IDIAP Jordi Gol) and the Institute of Biomedical Research in Girona (IdIBGi). The first patients, who have been taking part since March and who are aged between 35 and 74, are from the EAP Montilivi and it is expected that they will soon be joined by further participants from the EAP Celrà, to provide profiles of both urban and rural populations.

    Més informació "System developed for self-management of cardiovascular risk"

  • 16/06/2016 - Press release

    When is the best time to have carotid stenosis surgery after a stroke?

    An international study led by the Neurology Service at Hospital del Mar and the Neurovascular research group at the Hospital del Mar Medical Research Institute (IMIM) has quantified the risk and developed predictors for ischemic stroke in patients with carotid artery stenosis. The results of the study, published in the journal Neurology, have confirmed that there is a high risk of recurrence in the first 14 days after the stroke, which is the recommended time for carotid revascularisation surgery. But since very urgent surgery entails a considerable surgical risk, it is necessary to determine the most appropriate time for undertaking this operation in the fourteen days following the stroke. The study provides a starting point and randomised trials are recommended to determine the benefits and safety of emergency revascularisation as opposed to subacute carotid revascularisation within 14 days after the onset of symptoms.

    Més informació "When is the best time to have carotid stenosis surgery after a stroke?"

  • 15/06/2016 - Press release

    BIB launches its website to boost visibility of catalan bioinformatic potential

    Bioinformatics Barcelona Association (BIB) launches its, which aims to be a reference in the bioinformatic sector at national and international level, and to become the platform for communication and interaction among BIB's partners. Through this website, the association has enhanced its digital presence to become a meeting-point facilitator of initiatives and a think tank for the bioinformatic community. The portal contains sections on the BIB partners and their research groups in the bioinformatic field, and on education and training, job offers and internships, news, activities and news clipping, as well as a section with specific information on the association itself. The website aims to boost the international visibility of our ready-and-available bioinformatic strength, which, through collaboration among partners and together with external agents, can extend current limits to achieve increasingly ambitious goals.

    Més informació "BIB launches its website to boost visibility of catalan bioinformatic potential"

  • 07/06/2016 - Press release

    Clinical trial opens new avenues for pharmacological therapy in Down’s syndrome

    A team of scientists led by doctors Rafael de la Torre at Hospital del Mar Medical Research Institute (IMIM) and Mara Dierssen at the Centre for Genomic Regulation (CRG) have shown that epigallocatechin gallate together with a cognitive stimulation protocol, might improve some cognitive domains in individuals with Down’s syndrome.   The results of the phase 2 study will be published on 6th June in the prestigious journal The Lancet Neurology. The findings suggest that participants who had received the treatment had better scores in the visual memory recognition and inhibition tasks, and improvement in adaptive behaviour than those in the control group (placebo and cognitive training). Though not a cure, this is the first time that a treatment has shown some effectiveness in this syndrome, and it opens the door to new research geared towards treating what was believed to be orphan of treatment.

    Més informació "Clinical trial opens new avenues for pharmacological therapy in Down’s syndrome"

  • 26/05/2016 - Press release

    European project eTOX launches a new video

    When bringing to market any new drug efficiency and safety are essential. R+D Departments in pharmaceutical companies spend lots of efforts to make sure the new compounds meet the highest standards. In the process, large amounts of useful information are produced, that traditionally end up buried in the archives of pharmaceutical companies. Committed to avoiding duplicating processes, wasting time and resources, 13 pharmaceutical industries, 7 academic institutions and 5 SMEs launched the eTOX project. The result of the project will be a comprehensive database with toxicity studies for thousands of drugs (or drug candidates) and a collection of original software applications for toxicity prediction. 

    Més informació "European project eTOX launches a new video"


Head of Communications:
Rosa Manaut(ELIMINAR)

Communications office:
Marta Calsina(ELIMINAR)

(+34) 93 316 06 80
(+34) 699 094 833

Doctor Aiguader, 88
08003 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact